IL21 and influenza: To test our hypothesis, we administered influenza vaccination in a prime/boost/boost strategy at 3-month intervals with and without s.c. IL-21–IgFc administration on days –2, 0, and 7 of each vaccination in the NHP model of SIV infection in aged RMs.